Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
about
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in SpainLung transplantation for cystic fibrosis: results, indications, complications, and controversies.Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?Efficacy and safety of current drug therapies for invasive aspergillosis.Voriconazole in clinical practice.Combination antifungal therapy for invasive fungal infections in children and adults.Antifungal combination therapy for invasive aspergillosis.Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.Current role of echinocandins in the management of invasive aspergillosis.Recent Advancements in Combinational Antifungal Therapy and Immunotherapy
P2860
Q30873926-B6FE7F51-470F-419F-B29C-92D230E96539Q33982322-15F53453-A276-469E-8C2E-360B1C3059B8Q34543970-267B24B3-A774-402D-9870-CB5E96BC02BDQ34549917-4968E825-EDF9-4D49-B448-7C5DA7710A99Q36658777-69174CAC-EB57-4B88-9250-302C51F0A303Q37373785-64E4B000-A860-4B9B-B017-410406EDC93AQ37944001-90CC03B3-AD0F-45D8-8D69-BE4C8ACD6A95Q38061736-16DC5F1B-A990-4C27-AEB9-18608AAE50B2Q38102782-F060E32B-5C7A-4A7D-A2C6-E4D6EC1B18F9Q38232492-ACA94DA4-A19C-440F-B491-F0A151F43193Q38284463-93CC14FE-C457-4ED8-A859-E9ED74199770Q38296370-E0A0BF1A-1FBC-4A74-B98E-6AD3C8F90F5BQ38871233-40B5DECC-839E-4685-83EC-F56988E8D0F5Q39196802-947F7A53-D70F-458A-B14A-680B72A7C245Q42706346-772D254E-0E04-491D-9D6F-4B1EE3210683Q43718029-86381019-12F7-4C3E-85F9-DDFE049B2101Q53217028-701CE80E-B86C-4B08-9378-B49AE3ADB4FEQ57705351-10E81490-6220-4C31-BD1B-D45A5AAF3E78
P2860
Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Does combination of lipid form ...... tological malignancy patients?
@en
Does combination of lipid form ...... tological malignancy patients?
@nl
type
label
Does combination of lipid form ...... tological malignancy patients?
@en
Does combination of lipid form ...... tological malignancy patients?
@nl
prefLabel
Does combination of lipid form ...... tological malignancy patients?
@en
Does combination of lipid form ...... tological malignancy patients?
@nl
P2093
P2860
P356
P1433
P1476
Does combination of lipid form ...... tological malignancy patients?
@en
P2093
Christelle Kassis
Coralia N Mihu
Elizabeth R Ramos
Issam I Raad
Ray Y Hachem
Ying Jiang
P2860
P304
P356
10.1002/CNCR.25312
P407
P577
2010-11-01T00:00:00Z